Exogenus Therapeutics announces that its exclusively licensed patent entitled “USE OF UMBILICAL CORD BLOOD DERIVED EXOSOMES FOR TISSUE REPAIR” has been granted in China and Korea.
The patent describes the use of extracellular vesicles secreted by umbilical cord blood mononuclear cells as a therapeutic tool for tissue regeneration. Umbilical cord blood is a cell source with a strong therapeutic potential, that can be mediated by extracellular vesicles carrying specific microRNAs.
Exogenus has been demonstrating the use of extracellular vesicles from umbilical cord blood as a therapeutic application for different applications, including tissue regeneration. The grant of this licensed patent in China and Korea strengthens Exogenus international IP positioning within the extracellular vesicles’ therapeutics space. Additionally, this reflects Exogenus commitment to perform science that can have a positive impact on people’s life.
Exogenus is one of the world’s leading extracellular vesicles biotech companies. Exogenus’ mission is to bring innovative, effective and safe therapies to patients. In the near future, Exogenus aims to expand the use of these proprietary extracellular vesicles as an option for treatment of other regenerative disorders and inflammatory diseases.